Bone remodelling markers in rheumatoid arthritis

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Fardellone, Patrice ^a,b   Séjourné, Alice ^a   Paccou, Julien ^a,b   Goëb, Vincent ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; COLLAGEN TYPE 1; DICKKOPF 1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RITUXIMAB; SCLEROSTIN; STROMELYSIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR; ACID PHOSPHATASE; AMINO ACID; ISOENZYME; PYRIDINOLINE; TARTRATE-RESISTANT ACID PHOSPHATASE;

BODY MASS; BONE DEMINERALIZATION; BONE DENSITY; BONE EROSION; BONE METABOLISM; BONE REMODELING; CELL DIFFERENTIATION; CORTICAL BONE; HUMAN; JOINT CAVITY; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY; ANIMAL; METABOLISM; PHYSIOLOGY;

ACID PHOSPHATASE; AMINO ACIDS; ANIMALS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE REMODELING; COLLAGEN TYPE I; HUMANS; ISOENZYMES;

EID: 84899984543     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/484280     Document Type: Review

References (46)

1. Hougeberg G., Lodder M. C., Lems W. F., Uhlig T., Orstavik R. E., Dijkmans B. A., Kvien T. K., Woolf A. D., Hand cortical bone mass and its associations with radiographic joint damage and fractures in 50-70 year old female patients with rheumatoid arthritis: cross sectional Oslo-Truro-Amsterdam (OSTRA) collaborative study. Annals of the Rheumatic Diseases 2004 63 10 1331 1334 2-s2.0-4644257040 10.1136/ard.2003.015065 (Pubitemid 39273517)
2. Lodder M. C., Haugeberg G., Lems W. F., Uhlig T., Orstavik R. E., Kostense P. J., Dijkmans B. A. C., Kvien T. K., Woolf A. D., Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the Oslo-Truro-Amsterdam (OSTRA) collaborative study. Arthritis Care and Research 2003 49 2 209 215 2-s2.0-0345269749 (Pubitemid 36418279)
3. Forsblad d'Elia H., Larsen A., Waltbrand E., Kvist G., Mellstrom D., Saxne T., Ohlsson C., Nordborg E., Carlsten H., Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Annals of the Rheumatic Diseases 2003 62 7 617 623 2-s2.0-0038208285 10.1136/ard.62.7.617 (Pubitemid 36760557)
4. Jensen T., Hansen M., Jensen K. E., Podenphant J., Hansen T. M., Hyldstrup L., Comparison of dual X-ray absorptiometry (DXA), digital X-ray radiogrammetry (DXR), and conventional radiographs in the evaluation of osteoporosis and bone erosions in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology 2005 34 1 27 33 2-s2.0-15944412923 10.1080/03009740510017986 (Pubitemid 40445055)
5. Stewart A., Mackenzie L. M., Black A. J., Reid D. M., Predicting erosive disease in rheumatoid arthritis. A longitudinal study of changes in bone density using digital X-ray radiogrammetry: a pilot study. Rheumatology 2004 43 12 1561 1564 2-s2.0-10444241015 10.1093/rheumatology/keh385 (Pubitemid 39642583)
6. Green M. J., Deodhar A. A., Bone changes in early rheumatoid arthritis. Best Practice and Research: Clinical Rheumatology 2001 15 1 105 123 2-s2.0-0035041256 10.1053/berh.2000.0129 (Pubitemid 32396433)
7. Boyle W. J., Simonet W. S., Lacey D. L., Osteoclast differentiation and activation. Nature 2003 423 6937 337 342 2-s2.0-0037673945 10.1038/nature01658 (Pubitemid 40852708)
8. Hofbauer L. C., Kuhne C. A., Viereck V., The OPG/RANKL/RANK system in metabolic bone diseases. Journal of Musculoskeletal & Neuronal Interactions 2004 4 3 268 275 2-s2.0-8644276338 (Pubitemid 39504354)
9. Hofbauer L. C., Lacey D. L., Dunstan C. R., Spelsberg T. C., Riggs B. L., Khosla S., Interleukin-1 β and tumor necrosis factor- α but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999 25 3 255 259 2-s2.0-0032588998 10.1016/S8756-3282(99)00162-3 (Pubitemid 29406050)
10. Bezerra M. C., Carvalho J. F., Prokopowitsch A. S., Pereira R. M., RANK, RANKL and osteoprotegerin in arthritic bone loss. Brazilian Journal of Medical and Biological Research 2005 38 2 161 170 2-s2.0-15044344799 (Pubitemid 40378401)
11. Barnabe C., Hanley D. A., Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Seminars in Arthritis and Rheumatism 2009 39 2 116 122 2-s2.0-70349454163 10.1016/j.semarthrit.2008.04.004
12. Sakthiswary R., Das S., The effects of TNF α antagonist therapy on bone metabolism in rheumatoid arthritis: a systematic review. Current Drug Targets 2013 14 13 1552 1557 10.2174/13894501113149990176
13. van Tuyl L. H., Voskuyl A. E., Boers M., Geusens P., Landewé R. B., Dijkmans B. A., Lems W. F., Baseline RANKL: OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Annals of the Rheumatic Diseases 2010 69 9 1623 1628 2-s2.0-77956050875 10.1136/ard.2009.121764
14. Gonzales-Alvaro I., Ortiz A. M., Tomero E. G., Balsa A., Orte J., Laffon A., Garcia-Vicuña R., Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Annals of the Rheumatic Diseases 2007 66 12 1675 1678 2-s2.0-36749086534 10.1136/ard.2007.071910 (Pubitemid 350205461)
15. Catrina A. I., Af Klint E., Ernestam S., Catrina S. B., Makrygiannakis D., Botusan I. R., Klareskog L., Ulfgren A. K., Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis & Rheumatism 2006 54 1 76 81 2-s2.0-31044434410 10.1002/art.21528 (Pubitemid 43122189)
16. Dore R. K., Cohen S. B., Lane N. E., Palmer W., Shergy W., Zhou L., Wang H., Tsuji W., Newmark R., Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Annals of the Rheumatic Diseases 2010 69 5 872 875 2-s2.0-77951565454 10.1136/ard.2009.112920
17. Heiland G. R., Zwerina K., Baum W., Kireva T., Distler J. H., Grisanti M., Asuncion F., Li X., Ominsky M., Richards W., Schett G., Zwerina J., Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Annals of the Rheumatic Diseases 2010 69 12 2152 2159 2-s2.0-78649723963 10.1136/ard.2010.132852
18. Garnero P., Charni-Tabassi N., Voorzanger-Rousselot N., Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. The Journal of Rheumatology 2008 35 12 2313 2315 2-s2.0-57349120155 10.3899/jrheum.080356
19. Hashizume M., Hayakawa N., Mihara M., IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF- α and IL-17. Rheumatology 2008 47 11 1635 1640 2-s2.0-54449101331 10.1093/rheumatology/ken363
20. Wong P. K., Quinn J. M., Sims N. A., van Nieuwenhuijze A., Campbell I. K., Wicks I. P., Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis & Rheumatism 2006 54 1 158 168 2-s2.0-31044449633 10.1002/art.21537 (Pubitemid 43122198)
21. Chopin F., Garnero P., le Henanff A., Debiais F., Daragon A., Roux C., Sany J., Wendling D., Zamitsky C., Ravaud P., Thomas T., Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2008 67 3 353 357 2-s2.0-39549116297 10.1136/ard.2007.076604 (Pubitemid 351281270)
22. Garnero P., Delmas P. D., Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers. Current Opinion in Rheumatology 2004 16 4 428 434 10.1097/01.moo.0000127830.72761.00 (Pubitemid 38803145)
23. Gravallese E. M., Bone destruction in arthritis. Annals of the Rheumatic Diseases 2002 61 supplement 2 ii84 ii86 2-s2.0-0036839553 (Pubitemid 35221724)
24. Garnero P., Landewe R., Boers M., Verhoeven A., van der Linden S., Christgau S., van der Heijde D., Boonen A., Geusens P., Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis. Arthritis & Rheumatism 2002 46 11 2847 2856 2-s2.0-0036846269 10.1002/art.10616 (Pubitemid 35315875)
25. Straburzyńska-Lupa A., Nowak A., Romanowski W., Korman P., Pilaczyńska-Szcześniak L., A study of the link between bone turnover markers and bone mineral density with inflammation and body mass in postmenopausal women with active rheumatoid arthritis. Journal of Bone and Mineral Metabolism 2013 31 2 169 176 10.1007/s00774-012-0400-2
26. Szentpetery A., McKenna M. J., Murray B. F., Ng C. T., Brady J. J., Morrin M., Radovits B., Veale D. J., Fitzgerald O., Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis. The Journal of Rheumatology 2013 40 5 653 662 10.3899/jrheum.120397
27. Vis M., Havaardsholm E. A., Haugeberg G., Uhlig T., Voskuyl A. E., van de Stadt R. J., Dijkmans B. A., Woolf A. D., Kvien T. K., Lems W. F., Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NF B ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2006 65 11 1495 1499 2-s2.0-33749150667 10.1136/ard.2005.044198 (Pubitemid 44629129)
28. Güler-Yüksel M., Allaart C. F., Goekoop-Ruiterman Y. P., de Vries-Bouwstra J. K., van Groenendael J. H., Mallée C., de Bois M. H., Breedveld F. C., Dijkmans B. A., Lems W. F., Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Annals of the Rheumatic Diseases 2009 68 3 330 336 2-s2.0-61449124076 10.1136/ard.2007.086348
29. Marotte H., Pallot-Prades B., Grange L., Gaudin P., Alexandre C., Miossec P., A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Research & Therapy 2007 9 3, article R61 2-s2.0-34548443592 10.1186/ar2219
30. Seriolo B., Paolino S., Sulli A., Ferretti V., Cutolo M., Bone metabolism changes during anti-TNF- α therapy in patients with active rheumatoid arthritis. Annals of the New York Academy of Sciences 2006 1069 420 427 2-s2.0-33745593028 10.1196/annals.1351.040 (Pubitemid 43989885)
31. Briot K., Garnero P., le Henanff A., Dougados M., Roux C., Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment. Annals of the Rheumatic Diseases 2005 64 8 1137 1140 2-s2.0-22244433242 10.1136/ard.2004. 028670 (Pubitemid 41113346)
32. Lange U., Teichmann J., Muller-Ladner U., Strunk J., Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF- α antibody: a prospective open-label pilot study. Rheumatology 2005 44 12 1546 1548 2-s2.0-28544447762 10.1093/rheumatology/kei082 (Pubitemid 41742473)
33. Axmann R., Böhm C., Krönke G., Zwerina J., Smolen J., Schett G., Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis & Rheumatism 2009 60 9 2747 2756 2-s2.0-69449090213 10.1002/art.24781
34. Terpos E., Fragiadaki K., Konsta M., Bratengeier C., Papatheodorou A., Sfikakis P. P., Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clinical and Experimental Rheumatology 2011 29 6 921 925 2-s2.0-84857534016
35. Garnero P., Thompson E., Woodworth T., Smolen J. S., Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis & Rheumatism 2010 62 1 33 43 2-s2.0-74849102659 10.1002/art.25053
36. Kanbe K., Nakamura A., Inoue Y., Hobo K., Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis. Rheumatology International 2012 32 9 2669 2674 2-s2.0-79960556769 10.1007/s00296-011-2021-9
37. Karsdal M. A., Schett G., Emery P., Harari O., Byrjalsen I., Kenwright A., Bay-Jensen A. C., Platt A., IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Seminars in Arthritis and Rheumatism 2012 42 2 131 139 2-s2.0-84857660096 10.1016/j.semarthrit.2012. 01.004
38. Hashimoto J., Garnero P., van der Heijde D., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Yoshikawa H., Nishimoto N., Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Modern Rheumatology 2011 21 1 10 15 2-s2.0-79951942809 10.1007/s10165-010-0325-3
39. Onal M., Xiong J., Chen X., Receptor activator of nuclear factor B ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. The Journal of Biological Chemistry 2012 287 29851 29860 10.1074/jbc.M112.377945
40. Hein G., Eidner T., Oelzner P., Rose M., Wilke A., Wolf G., Franke S., Influence of rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study. Rheumatology International 2011 31 2 269 272 2-s2.0-79954435995 10.1007/s00296-010-1560-9
41. de Hair M. J., Zijlstra I. A., Boumans M. J., van de Sande M. G., Maas M., Gerlag D. M., Tak P. P., Hunting for the pathogenesis of rheumatoid arthritis: core-needle biopsy of inguinal lymph nodes as a new research tool. Annals of the Rheumatic Diseases 2012 71 11 1911 1912 10.1136/annrheumdis-2012- 201540
42. Hein G., Eidner T., Oelzner P., Rose M., Wilke A., Wolf G., Franke S., Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study. Rheumatology International 2011 31 2 269 272 2-s2.0-79954435995 10.1007/s00296-010-1560-9
43. Goëb V., Buch M. H., Vital E. M., Emery P., Costimulation blockade in rheumatic diseases: where we are? Current Opinion in Rheumatology 2009 21 3 244 250 10.1097/BOR.0b013e328329a401
44. Axmann R., Herman S., Zaiss M., Franz S., Polzer K., Zwerina J., Herrmann M., Smolen J., Schett G., CTLA-4 directly inhibits osteoclast formation. Annals of the Rheumatic Diseases 2008 67 11 1603 1609 2-s2.0-47249103596 10.1136/ard.2007.080713
45. Cutolo M., Nadler S. G., Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmunity Reviews 2013 12 7 758 767 10.1016/j.autrev.2013.01.001
46. Bedi B., Li J.-Y., Grassi F., Tawfeek H., Weitzmann M. N., Pacifici R., Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss. Annals of the New York Academy of Sciences 2010 1192 215 221 2-s2.0-77950663905 10.1111/j.1749-6632.2009.05216.x